---
title: "禮來：80% 使用奧姆沃的患者實現長期緩解。3 期 LUCENT - 2 研究進行到一年時，78% 的患者實現了無需使用皮質類固醇的臨牀緩解。"
description: "禮來：80% 使用奧姆沃的患者實現長期緩解。3 期 LUCENT - 2 研究進行到一年時，78% 的患者實現了無需使用皮質類固醇的臨牀緩解。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/260149476.md"
published_at: "2025-10-07T10:47:01.000Z"
---

# 禮來：80% 使用奧姆沃的患者實現長期緩解。3 期 LUCENT - 2 研究進行到一年時，78% 的患者實現了無需使用皮質類固醇的臨牀緩解。

禮來：80% 使用奧姆沃的患者實現長期緩解。3 期 LUCENT - 2 研究進行到一年時，78% 的患者實現了無需使用皮質類固醇的臨牀緩解。

### Related Stocks

- [LLY.US - 禮來](https://longbridge.com/zh-HK/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co statement | Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co | [Link](https://longbridge.com/zh-HK/news/275551012.md) |
| Eli Lilly and Company $LLY Shares Acquired by Assetmark Inc. | Assetmark Inc. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 6.0% in Q3, owning 55,360 shares valued at | [Link](https://longbridge.com/zh-HK/news/275971336.md) |
| China's Innovent clinches new Lilly deal for immunology, cancer drug development | China’s Innovent Biologics has secured a new deal with Eli Lilly for the development of immunology and oncology drugs, i | [Link](https://longbridge.com/zh-HK/news/275255059.md) |
| Bessemer Group Inc. Acquires 48,062 Shares of Eli Lilly and Company $LLY | Bessemer Group Inc. increased its stake in Eli Lilly and Company by 14.5%, acquiring an additional 48,062 shares, bringi | [Link](https://longbridge.com/zh-HK/news/274952193.md) |
| Lilly's bowel disease drug gets approval in China  | Eli Lilly has received approval from Chinese regulators for its drug mirikizumab, aimed at treating chronic inflammatory | [Link](https://longbridge.com/zh-HK/news/275554667.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
